A Empresa

Hitag Biotechnology is dedicated to develop recombinant proteins and immunogens without the need for adjuvants. By using a proprietary platform, “Fh8 r-PPure System”, Hitag Biotechnology produces soluble and highly pure recombinant proteins. This platform relies in the smallest solubilisation tag, 8 kDa, which has affinity to hydrophobic purification colums. A second proprietary platform, “H VerImmune Ligand”, conferes to a recombinant antigen the immunogenic features of a peptide. The immunisation procedure of this recombinant immunogen does not requires coadministration of adjuvant.
 
Hitag Biotechnology is placed in Biocant Park, a Biotechnology Technological Park located in Portugal, and owns the Hitag trademark.